Lufepirsen gel for persistent corneal epithelial defects
Part of Eyes & vision clinical trials.
This Phase 2 trial tests whether a treatment gel called NEXAGON (lufepirsen) can improve healing and safety in people with a persistent corneal problem called PCED that hasn’t gotten better despite standard non-surgical treatments. You may be a candidate if your defect has lasted at least 2 weeks and hasn’t improved recently, and if you don’t have certain eye infections or other eye conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have PCED in the study eye lasting at least 2 weeks
- Your PCED has not improved after at least one standard non-surgical eye treatment
- Your PCED has shown no clinical improvement in the 2 weeks before starting the study
- Be able to give written consent (or assent, if applicable)
- If you can become pregnant: be at least 1 year past menopause, surgically unable to become pregnant, or have a negative urine pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether cenegermin eye drops help heal stubborn corneal ulcers (open sores on the clear front of the eye) that haven't improved with standard treatments like lubricating drops or contact lenses.
This study tests whether a special substance from stem cells (called secretome) can help heal chronic surface problems on the eye that haven't gotten better with standard treatments. It's for people with a stubborn scratch or defect on the cornea that has lasted more than 14 days.
This Phase 3 trial tests whether a 0.1% RGN-259 eye drop can safely improve a stubborn corneal wound in adults with neurotrophic keratopathy (nerve-related corneal healing problems). You may qualify if you still have an eye surface defect after at least a week of standard treatments, and you meet specific measurements for corneal sensitivity and vision.
This Phase 2 trial tests a locally delivered cell-based treatment (allogeneic mesenchymal stromal cells) to help heal long-lasting damage to the eye’s clear surface (the cornea). It may help if your cornea epithelium (surface layer) won’t improve even after standard non-surgical treatments.
This trial tests whether a new eye drop called Lacripep can help treat neurotrophic keratitis, a rare eye condition where the cornea loses sensation and can become damaged. The study compares Lacripep to a placebo (inactive) drop to see if it improves corneal healing and vision.
This trial tests a new corneal implant to treat corneal swelling caused by Fuchs' dystrophy or after cataract surgery. It aims to improve vision and reduce the need for a full corneal transplant.
Hear when a new Persistent Corneal Epithelial Defect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.